Xofluza Approved to Treat and Prevent Flu in Children 5 to 12 Years Old
Drugmaker Genentech announced that the U.S. Food and Drug Administration (FDA) approved its flu drug Xofluza for children ages 5 to 12.The FDA greenlighted a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children who have been symptomatic for no more than 48 hours, according to a statement released last week by the company. Xofluza is the first single-dose oral influenza medicine that’s been approved for children in this age group.Additionally, the FDA approved Xofluza to help prevent influenza in children in this age group following contact with someone with the flu.“Despite the ongoing COVID-19 pandemic, influenza continues to be a threat to public health, and effective influenza antivirals remain critical to alleviating the burden on healthcare systems,” said Levi…